Ampligen - More test is call for. So another 6 month, plus delay.

[Guest guest]

PHILADELPHIA, Dec. 1, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE

Amex:HEB) (the " Company " or " Hemispherx " ), announced that it received a Complete

Response Letter from the U.S. Food and Drug Administration ( " FDA " ) which

describes specific additional recommendations related to the Ampligen® NDA. In

accordance with its 2008 " Complete Response " procedure, the FDA reviewers

determined that they cannot approve the application in its present form and

provided specific recommendations to address the outstanding issues. Hemispherx

is carefully reviewing the Complete Response letter and will seek an expedited

meeting with the FDA to discuss its recommendations. Management is pleased to

have received specific advice on the remaining issues and is looking forward to

making a thorough but expedited response its top priority, and plans to take all

appropriate steps to seek approval and commercialization of Ampligen®.

Thursday 10:00 there will be a conference call.

This call will be webcast via the Company's website at:

http://www.hemispherx.net.